DK2140870T3 - Bærestofsammensætning til øjeblikkelig nukleinsyrefremføring - Google Patents
Bærestofsammensætning til øjeblikkelig nukleinsyrefremføring Download PDFInfo
- Publication number
- DK2140870T3 DK2140870T3 DK08738918.5T DK08738918T DK2140870T3 DK 2140870 T3 DK2140870 T3 DK 2140870T3 DK 08738918 T DK08738918 T DK 08738918T DK 2140870 T3 DK2140870 T3 DK 2140870T3
- Authority
- DK
- Denmark
- Prior art keywords
- sirna
- composition
- delivery
- sirna delivery
- cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (12)
1. Sammensætning til siRNA-fremføring, omfattende et siRNA, og en bærestofsammensætning til siRNA-fremføring, omfattende (A) et diacylphosphati-dylcholin, (B) mindst ét element valgt fra gruppen bestående af cholesterol og kationiske lipider, der har et cholesterolskelet, og (C) en alifatisk primær amin.
2. Sammensætning til siRNA-fremføring ifølge krav 1, hvor bestanddelen (A) er et diacylphosphatidylcholin, hvis acyl-gruppedel har 4 til 23 carbonatomer.
3. Sammensætning til siRNA-fremføring ifølge krav 1 eller 2, hvor bestanddelen (B) er cholesterol.
4. Sammensætning til siRNA-fremføring ifølge et hvilket som helst af krav 1-3, hvor bestanddelen (C) er en alkylamin, der har 10 til 20 carbonatomer.
5. Sammensætning til siRNA-fremføring ifølge krav 1, hvor bestanddelen (A) er mindst ét element valgt fra gruppen bestående af dimy-ristoylphosphatidylcholin, dipalmitoylphosphatidylcholin, og distearoylphosphatidylcholin; bestanddelen (B) er cholesterol; og bestanddelen (C) er stearylamin.
6. Sammensætning til siRNA-fremføring ifølge et hvilket som helst af krav 1-5, hvor molforholdet af bestanddel (A):bestanddel (B):bestanddel (C) er 5-9:1-5:1.
7. Sammensætning til siRNA fremføring ifølge et hvilket som helst af krav 1-6, hvor bærestofsammensætningen til siRNA-fremføring er en liposom-sammensætning hvor en liposom-membran er dannet af bestanddelene (A) til (C).
8. Sammensætning til siRNA-fremføring ifølge et hvilket som helst af krav 1-6, som er en liposom-sammensætning.
9. Sammensætning ifølge et hvilket som helst af krav 1-8 til anvendelse i medicin.
10. Sammensætning ifølge et hvilket som helst af krav 1-8 til anvendelse i inhiberin-gen af ekspressionen af et målgen i celler eksisterende i levende organismer.
11. Anvendelse af en bærestofssammensætning omfattende (A) et diacylphosphatidylcholin, (B) mindst ét element valgt fra gruppen bestående af cholesterol og kationiske lipider, der har et cholesterolskelet, og (C) en alifatisk primær amin og et siRNA til fremstilling af sammensætningen ifølge et hvilket som helst af krav 1-10.
12. Fremgangsmåde til indføring af et siRNA, hvilket omfatter trinnet at indføre siR-NAet i dyrkede celler eller celler separeret fra levende organismer ved at bringe sammensætningen til siRNA-fremføring ifølge krav 1 i kontakt med cellerne.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007079944 | 2007-03-26 | ||
PCT/JP2008/055730 WO2008117828A1 (ja) | 2007-03-26 | 2008-03-26 | 即効型核酸送達用キャリアー組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2140870T3 true DK2140870T3 (da) | 2015-07-20 |
Family
ID=39788561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08738918.5T DK2140870T3 (da) | 2007-03-26 | 2008-03-26 | Bærestofsammensætning til øjeblikkelig nukleinsyrefremføring |
Country Status (27)
Country | Link |
---|---|
US (1) | US9315828B2 (da) |
EP (1) | EP2140870B1 (da) |
JP (1) | JP5349293B2 (da) |
KR (1) | KR101459391B1 (da) |
CN (1) | CN101646443B (da) |
AR (1) | AR065847A1 (da) |
AU (1) | AU2008230379B2 (da) |
BR (1) | BRPI0809634A2 (da) |
CA (1) | CA2682490A1 (da) |
CO (1) | CO6241127A2 (da) |
DK (1) | DK2140870T3 (da) |
ES (1) | ES2542864T3 (da) |
HK (1) | HK1139041A1 (da) |
HR (1) | HRP20150927T1 (da) |
HU (1) | HUE027053T2 (da) |
IL (1) | IL201116A0 (da) |
MX (1) | MX2009010336A (da) |
MY (1) | MY151450A (da) |
NZ (1) | NZ579804A (da) |
PL (1) | PL2140870T3 (da) |
PT (1) | PT2140870E (da) |
RU (1) | RU2476229C2 (da) |
SI (1) | SI2140870T1 (da) |
TW (1) | TWI428135B (da) |
UA (1) | UA97143C2 (da) |
WO (1) | WO2008117828A1 (da) |
ZA (1) | ZA200906576B (da) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5808246B2 (ja) * | 2009-03-04 | 2015-11-10 | 大塚製薬株式会社 | 核酸複合体、及び核酸送達用組成物 |
WO2011133658A1 (en) | 2010-04-22 | 2011-10-27 | Boston Medical Center Corporation | Compositions and methods for targeting and delivering therapeutics into cells |
CN103167866B (zh) | 2010-09-20 | 2015-09-23 | 瑟纳治疗公司 | 用于寡核苷酸递送的新型低分子量阳离子脂质 |
JP6029131B2 (ja) * | 2011-12-28 | 2016-11-24 | 国立研究開発法人国立循環器病研究センター | 核酸導入剤、核酸導入方法及び細胞 |
JP2020502124A (ja) | 2016-12-14 | 2020-01-23 | リガンダル インコーポレイテッド | 核酸および/またはタンパク質ペイロード送達のための組成物および方法 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0750910A4 (en) | 1994-03-11 | 1997-07-09 | Yoshitomi Pharmaceutical | PREPARATION OF LIPOSOMES |
US20030092180A1 (en) | 2001-08-27 | 2003-05-15 | David Lewis | Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo |
US6126964A (en) * | 1996-01-04 | 2000-10-03 | Mirus Corporation | Process of making a compound by forming a polymer from a template drug |
US6358523B1 (en) * | 1996-12-06 | 2002-03-19 | The Regents Of The University Of California | Macromolecule-lipid complexes and methods for making and regulating |
US6835395B1 (en) * | 1997-05-14 | 2004-12-28 | The University Of British Columbia | Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles |
JPH10313872A (ja) * | 1997-05-21 | 1998-12-02 | Soyaku Gijutsu Kenkyusho:Kk | 抗インフルエンザウイルス剤 |
US6740335B1 (en) * | 1997-09-16 | 2004-05-25 | Osi Pharmaceuticals, Inc. | Liposomal camptothecin formulations |
BR9812316A (pt) | 1997-09-16 | 2001-03-20 | Nexstar Pharmaceuticals Inc | Formulações de camptotecina lipossÈmica |
JPH11292795A (ja) * | 1998-04-02 | 1999-10-26 | Yamanouchi Pharmaceut Co Ltd | Hivコファクター抑制剤 |
JP4854853B2 (ja) | 1998-11-12 | 2012-01-18 | ライフ テクノロジーズ コーポレーション | トランスフェクション薬剤 |
CA2421409A1 (fr) * | 2000-09-08 | 2002-03-14 | Aventis Pasteur | Utilisation de lipopeptides pour l'immunotherapie des sujets vih+ |
US20060030578A1 (en) * | 2002-08-20 | 2006-02-09 | Neopharm, Inc. | Pharmaceutically active lipid based formulation of irinotecan |
AU2003296897A1 (en) | 2002-08-20 | 2004-05-04 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
EA008497B1 (ru) * | 2002-11-21 | 2007-06-29 | Певион Биотех Лтд. | Высокоэффективные способные к слиянию везикулы, способ их получения и фармацевтическая композиция, их содержащая |
WO2004064731A2 (en) * | 2003-01-14 | 2004-08-05 | University Of Washington | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymlplhoid tissues |
EP1640360A4 (en) * | 2003-06-27 | 2007-06-20 | Sumitomo Chemical Co | AMIDE AND METHOD FOR COMBATING PLANT DISEASES THEREFOR |
AU2004257373B2 (en) * | 2003-07-16 | 2011-03-24 | Arbutus Biopharma Corporation | Lipid encapsulated interfering RNA |
WO2005027979A2 (en) * | 2003-09-17 | 2005-03-31 | Let There Be Hope Medical Research Institute | Targeted lipid-drug formulations for delivery of drugs to myeloid and lymphoid immune cells |
EP1759691A1 (en) | 2003-11-20 | 2007-03-07 | Delex Therapeutics Inc. | Stable liposome compositions |
AT500143A1 (de) * | 2004-04-22 | 2005-11-15 | Sanochemia Pharmazeutika Ag | Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung |
JP2005336081A (ja) * | 2004-05-26 | 2005-12-08 | Anges Mg Inc | Nr2b−nmda受容体の再発現抑制剤 |
AU2005259799A1 (en) * | 2004-07-02 | 2006-01-12 | Protiva Biotherapeutics, Inc. | Immunostimulatory siRNA molecules and uses therefor |
CA2587411A1 (en) * | 2004-11-17 | 2006-05-26 | Protiva Biotherapeutics, Inc. | Sirna silencing of apolipoprotein b |
CN101346468B (zh) * | 2005-06-15 | 2016-03-30 | 麻省理工学院 | 含胺脂质和其用途 |
US20070160658A1 (en) * | 2005-10-20 | 2007-07-12 | The Penn State Research Foundation | Delivery system for diagnostic and therapeutic agents |
UA97559C2 (uk) * | 2007-11-08 | 2012-02-27 | Оцука Фармасьютікал Ко., Лтд. | Комплекс нуклеїнової кислоти і композиція для доставки нуклеїнової кислоти |
-
2008
- 2008-03-25 TW TW097110544A patent/TWI428135B/zh not_active IP Right Cessation
- 2008-03-26 UA UAA200910735A patent/UA97143C2/ru unknown
- 2008-03-26 PL PL08738918T patent/PL2140870T3/pl unknown
- 2008-03-26 MX MX2009010336A patent/MX2009010336A/es active IP Right Grant
- 2008-03-26 HU HUE08738918A patent/HUE027053T2/en unknown
- 2008-03-26 SI SI200831495T patent/SI2140870T1/sl unknown
- 2008-03-26 US US12/532,949 patent/US9315828B2/en not_active Expired - Fee Related
- 2008-03-26 ES ES08738918.5T patent/ES2542864T3/es active Active
- 2008-03-26 MY MYPI20093905 patent/MY151450A/en unknown
- 2008-03-26 AU AU2008230379A patent/AU2008230379B2/en not_active Ceased
- 2008-03-26 KR KR1020097021571A patent/KR101459391B1/ko not_active IP Right Cessation
- 2008-03-26 RU RU2009139246/15A patent/RU2476229C2/ru not_active IP Right Cessation
- 2008-03-26 WO PCT/JP2008/055730 patent/WO2008117828A1/ja active Application Filing
- 2008-03-26 NZ NZ579804A patent/NZ579804A/en not_active IP Right Cessation
- 2008-03-26 EP EP08738918.5A patent/EP2140870B1/en active Active
- 2008-03-26 PT PT87389185T patent/PT2140870E/pt unknown
- 2008-03-26 BR BRPI0809634-1A2A patent/BRPI0809634A2/pt not_active IP Right Cessation
- 2008-03-26 CA CA002682490A patent/CA2682490A1/en not_active Abandoned
- 2008-03-26 JP JP2009506363A patent/JP5349293B2/ja active Active
- 2008-03-26 DK DK08738918.5T patent/DK2140870T3/da active
- 2008-03-26 AR ARP080101222A patent/AR065847A1/es unknown
- 2008-03-26 CN CN200880010035.6A patent/CN101646443B/zh not_active Expired - Fee Related
-
2009
- 2009-09-21 ZA ZA2009/06576A patent/ZA200906576B/en unknown
- 2009-09-23 IL IL201116A patent/IL201116A0/en unknown
- 2009-10-26 CO CO09120191A patent/CO6241127A2/es active IP Right Grant
-
2010
- 2010-05-14 HK HK10104730.5A patent/HK1139041A1/xx not_active IP Right Cessation
-
2015
- 2015-09-03 HR HRP20150927TT patent/HRP20150927T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2140870T3 (da) | Bærestofsammensætning til øjeblikkelig nukleinsyrefremføring | |
AU2006305318B2 (en) | Carrier composition for nucleic acid transport | |
JP5340282B2 (ja) | 核酸複合体、及び核酸送達用組成物 | |
US9090912B1 (en) | Nucleic acid complex and nucleic acid-delivering composition |